Apredica is a preclinical Contract Research Organization (CRO) that provides services to optimize and evaluate ADME, Toxicity and Pharmacokinetic properties of drug candidates and lead compounds early in the drug discovery process. In August 2010 Apredica (Watertown, MA) was acquired by Cyprotex (Macclesfield, UK) and now functions as their United States base of operations. As a wholly-owned subsidiary of Cyprotex, Apredica has continued to develop and validate industry-leading technologies, and now offers a High Content Screening Prediction system - CellCiphr®, that assists in evaluating potential toxic liabilities of compounds and genomic ADME (gADME™), a technology that combines genomic information about drug metabolizing enzymes and their alleles with ADME. As we expand the service offering for our clients, we remain dedicated to providing top-quality Caco-2 permeability and bioanalytical assays as part of a wide array of preclinical testing services.
Contact us to learn more about how Apredica can assist with your company's preclinical ADME, Toxicology, and PK studies.
Contact us to discuss how Apredica's ADME Tox testing services can help your organization increase the speed of drug discovery while reducing costs.